Compass Therapeutics, Inc. (CMPX)

NASDAQ: CMPX · Real-Time Price · USD
1.780
+0.020 (1.14%)
At close: May 8, 2025, 4:00 PM
1.760
-0.020 (-1.12%)
After-hours: May 8, 2025, 6:28 PM EDT
1.14%
Market Cap 246.14M
Revenue (ttm) 850,000
Net Income (ttm) -55.22M
Shares Out 138.28M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 611,190
Open 1.710
Previous Close 1.760
Day's Range 1.670 - 1.800
52-Week Range 0.765 - 4.080
Beta 1.19
Analysts Strong Buy
Price Target 13.57 (+662.36%)
Earnings Date May 8, 2025

About CMPX

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 35
Stock Exchange NASDAQ
Ticker Symbol CMPX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for CMPX stock is "Strong Buy." The 12-month stock price forecast is $13.57, which is an increase of 662.36% from the latest price.

Price Target
$13.57
(662.36% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (OR...

17 hours ago - GlobeNewsWire

Compass Therapeutics to Participate in Upcoming May Investor Events

BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, tod...

2 days ago - GlobeNewsWire

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors. Combining CTX-471 with tovecimig (CTX-009) markedly increased an...

10 days ago - GlobeNewsWire

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, a...

17 days ago - GlobeNewsWire

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...

5 weeks ago - GlobeNewsWire

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone,...

5 weeks ago - GlobeNewsWire

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical c...

5 weeks ago - GlobeNewsWire

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the firs...

2 months ago - GlobeNewsWire

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...

5 months ago - GlobeNewsWire

Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer

Compass Therapeutics' CTX-009 shows promise in biliary tract cancer, with a 37.5% response rate in phase 2 trials and a pivotal phase 2/3 readout expected in Q1 2025. Financially, CMPX is stable with ...

5 months ago - Seeking Alpha

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...

5 months ago - GlobeNewsWire

Compass Therapeutics to Participate in Upcoming Investor Events

BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...

6 months ago - GlobeNewsWire

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...

6 months ago - GlobeNewsWire

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, to...

6 months ago - GlobeNewsWire

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...

7 months ago - GlobeNewsWire

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...

9 months ago - GlobeNewsWire

Compass Therapeutics: Pointing Right At Some Tough Cancers

Compass Therapeutics is an oncology-focused biotech developing novel immunotherapies for solid tumors, with a focus on gastrointestinal cancers. Their most advanced candidate, CTX-009, targets DLL4 an...

11 months ago - Seeking Alpha

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...

1 year ago - GlobeNewsWire

Compass Therapeutics Announces CEO Transition

BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...

1 year ago - GlobeNewsWire

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...

1 year ago - GlobeNewsWire

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

BOSTON, May 14, 2024 (GLOBE NEWSWIRE) --  Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...

1 year ago - GlobeNewsWire

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...

1 year ago - GlobeNewsWire

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...

1 year ago - GlobeNewsWire

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...

1 year ago - GlobeNewsWire

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...

1 year ago - GlobeNewsWire